NYSE:GSK News | QuoteStream

prnewswire

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

LONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer…

PR Newswire en_IN 23/7/2026, 01:58 am GMT+8

StocksGBUS

GSK GSK

gurufocus

GSK Drops Chronic Cough Drug as Shares Fall 4.5%

GSK NYSE:GSK, a British drugmaker, has stopped developing camlipixant after concluding that the experimental treatment for refractory chronic cough was unlikely to transform patient care. The decision followed mixed late-stage results, with a high dose reducing cough frequency in one study but fail…

GuruFocus en_IN 21/7/2026, 12:44 am GMT+8

StocksGB